SciSparc Ltd. SPRC
Set alert
At close · Oct 30
After hours · Oct 30, 7:48 PM ET
- YTD
- -94.47%
- 1 year
- -97.69%
- Open
- 0.6769
- Prev close
- 0.7123
- Mkt cap
- 392.91K
- Vol
- 378.10K
- Avg vol
- 1.34M
- EPS
- 248.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6031
- High
- 0.6843
- Forward P/E
- 0.00
- Beta
- 1.04
- Short ratio
- 0.22
- Inst. own
- 1.73%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.23526
- 200-d avg
- 0.77116
- 1y target
- 0.00
Key statistics
- Market cap
- 2.41M
- Enterprise value
- 4.92K
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 0.12
- EPS (TTM)
- -5.28
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.75M
- Revenue growth
- -57.40%
- Free cash flow
- -3.97M
- Total cash
- 2.56M
- Total debt
- 64.00K
- Return on equity
- -85.91%
- Shares outstanding
- 10.36M
- Short % of float
- 0.93%
- 50-day average
- 0.23526
- 200-day average
- 0.77116
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About SciSparc Ltd.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- scisparc.com
News
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Dow Surges Over 200 Points; Verizon Shares Fall Following Q3 Results
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on SPRC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.67% | 69,006 | 16.06K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.36% | 37,082 | 8.63K | Sep 29, 2024 |
| Virtu Financial LLC | 0.14% | 14,106 | 3.28K | Sep 29, 2024 |
| Rhumbline Advisers | 0.03% | 3,464 | 806 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 238 | 55 | Sep 29, 2024 |